New York-based Definium Therapeutics, Inc. (Nasdaq: DFTX) announced a proposed underwritten public offering of USD 500 million in common shares and, to certain investors, pre-funded warrants, as it advances DT120 ODT toward potential approval and prepares for commercialization in psychiatric disorders. The capital raise reflects the cost burden of late-stage clinical development and pre-launch readiness activities for a psychedelic-derived compound navigating a regulatory pathway with limited precedent.
The offering is structured as a primary issuance of common shares, with pre-funded warrants available in lieu of common shares to select investors. Underwriters have been granted a 30-day option to purchase up to an additional USD 75 million in shares at the public offering price, bringing the potential total to USD 575 million. Specific pricing and share count had not been disclosed at announcement. J.P. Morgan, Jefferies, Leerink Partners, and BofA Securities are acting as joint lead bookrunners, with Evercore ISI and Stifel as additional bookrunners. Definium stated proceeds will fund research and development of its pipeline, pre-commercialization preparation for DT120 ODT if approved, and general working capital. The offering is being made under an existing shelf registration statement.
Company overview and pipeline
Definium Therapeutics, headquartered in New York, is a late-stage clinical biopharmaceutical company applying a drug development framework to psychedelic compounds, with the stated aim of addressing the underlying neurobiological causes of psychiatric and neurological disorders. The company rebranded from MindMed to Definium Therapeutics in January 2026, signaling a shift in positioning toward a more conventional pharmaceutical identity as it approaches potential regulatory milestones.
Its lead asset, DT120 ODT (lysergide D-tartrate), is an orally disintegrating tablet formulation of LSD developed using Catalent's Zydis fast-dissolve platform, designed to optimize bioavailability and reduce gastrointestinal side effects. The molecule functions as a partial serotonin receptor agonist and is hypothesized to promote neural connectivity relevant to anxiety-related network dysregulation. DT120 ODT is being evaluated in two pivotal Phase III studies — Voyage and Panorama — for generalized anxiety disorder (GAD). Management has indicated topline data from Voyage is anticipated in Q2 2026, with Panorama results expected in the second half of 2026. The company has explicitly linked the current financing to preparation activities for a potential commercial launch of DT120 ODT, indicating management expects near-term regulatory submissions contingent on data outcomes.